All In Biotech

Drug Trial Radar · NCT00710619

Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX

Dosing Observational Study in Hemophilia Subjects With Inhibitors: A Phase IV Diary Study in Subjects Prescribed NovoSeven® as First Line on Demand Therapy for Acute Bleeding Episodes

Last checked: Nov 19, 2026Latest source record: Nov 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Jun 2008

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jul 4, 2008

More drug trials from this sponsor

Design

Study type
Observational
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted in the United States of America (USA). The aim of this study is to investigate the at-home-administration of bypassing agents for treatment of bleeding episodes in patients with congenital haemophilia with inhibitors to factors VIII and IX. We are further investigating how bleeding episodes affect the quality of life of the patient and their family or caregivers.

Conditions

  • Congenital Bleeding Disorder
  • Haemophilia A With Inhibitors
  • Haemophilia B With Inhibitors

Interventions

  • activated recombinant human factor VIIDrug

    This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors

  • Feiba VHDrug

    This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Characterisation of dose and dosing intervals for each bleeding episodeTime frame: after 3-6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Plainsboro, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.